Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Mar. 31, 2019
Current assets:
Cash and cash equivalents	$ 130,373,000	$ 156,074,000
Marketable securities	27,220,000	0
Prepaid expenses and other current assets	9,969,000	10,194,000
Income tax receivable	17,000	524,000
Total current assets	167,579,000	166,792,000
Property and equipment, net	2,288,000	2,071,000
Operating lease right-of-use asset	8,973,000
Other assets	5,162,000	4,114,000
Total assets	184,002,000	172,977,000
Current liabilities:
Accounts payable	5,819,000	11,019,000
Interest payable	305,000	1,077,000
Accrued expenses	44,380,000	53,614,000
Operating lease liability	853,000
Due to Roivant Sciences Ltd. (RSL), Roivant Sciences, Inc. (RSI) and Roivant Sciences GmbH (RSG)	271,000	121,000
Current maturities of long-term debt	8,402,000	6,142,000
Total current liabilities	60,030,000	71,973,000
Deferred rent		1,157,000
Deferred interest payable	5,323,000	2,273,000
Long-term operating lease liability	9,320,000
Long-term debt, less current maturities	92,075,000	93,240,000
Total liabilities	166,748,000	168,643,000
Commitments and contingencies (Note 12)
Shareholders’ equity:
Common shares, par value $0.000017727 per share, 564,111,242 shares authorized, 89,623,564 and 72,057,490 issued and outstanding at September 30, 2019 and March 31, 2019, respectively	2,000	1,000
Additional paid-in capital	657,780,000	505,851,000
Accumulated other comprehensive (loss) income	(31,000)	507,000
Accumulated deficit	(640,497,000)	(502,025,000)
Total shareholders’ equity	17,254,000	4,334,000
Total liabilities and shareholders’ equity	$ 184,002,000	$ 172,977,000